NCT04648189

Cetuxibab to Reduce Circulating Tumor Cells in Early Stage NSCLC

Are Anti-EGFR Monoclonal Antibodies the Magic Bullets That Remove Circulating EGFR+EpCAM+ Tumor Cells in Patients With Non-small Cell Lung Cancer

• Status: Withdrawn
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: The Netherlands Cancer Institute · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Cetuximab to reduce the amound of circulating tumor cells in early stage NSCLC

Detailed description

A multicenter single arm phase II trial. 40 patients with pathology proven stage I-IIIA NSCLC that are eligible for resection will be enrolled in this study. All patients will receive one dose of cetuximab prior to surgery. Blood will be drawn on multiple timepoints to assess te amount of circulating tumor cells

Conditions

• Lung Cancer
• Surgery
• Circulating Tumor Cell

Interventions

Type	Name	Description
DRUG	Cetuximab	A single dose of cetuximab, 400mg/m2, will be administered 72 to 48 hours prior to surgery

Timeline

• Start date: 2022-01-01
• Primary completion: 2022-09-19
• Completion: 2022-09-19
• First posted: 2020-12-01
• Last updated: 2023-10-19

Locations

2 sites across 1 country: Netherlands